Cell Death and Disease · 2025 · 10 citations · 21 references
MedicineOncologyPharmacologyCancer PharmacologyCell SignalingMolecular OncologyHormonal Cancer TherapyProstate CancerSignal Transduction In CancerTherapeutic ResistanceAnti-androgen ResistanceCastration-resistant Prostate Cancer TherapyMolecular Drug ResistancePost-translational Modification SignalingProstate Cancer Hormonal TherapyProtein StabilityRegulation By E3 Ubiquitin LigasesReversal Of Drug Resistance
Advanced prostate cancer (PCa) is associated with a poor prognosis, particularly in patients who progress to castration-resistant prostate cancer (CRPC). The emergence of enzalutamide (Enz), a second-generation androgen receptor inhibitor, has effectively extended the median survival of these patients. However, drug resistance frequently develops during clinical use. Multiple studies have suggested that ferroptosis inducers can reverse cancer resistance to Enz, though the exact mechanisms remain unclear. In this study, we found that CRPC cells exhibit a concentration-dependent decrease in ferroptosis in response to Enz. This change is attributed to the upregulation of the protein level of SLC7A11. Protein stability assays and database analyses showed that SLC7A11 undergoes post-translational modification, likely connected to Enz-mediated downregulation of the SLC7A11-specific E3 ubiquitin ligase NEDD4L. This phenomenon was significantly reversed by the addition of erastin, a targeted inhibitor of the cystine/glutamate transport system Xc-. The data from both in vitro and in vivo experiments indicate that combining Enz with erastin significantly inhibits the proliferation of drug-resistant CRPC cells, thereby enhancing tumor suppression. These findings offer novel insights into targeting SLC7A11 with erastin as a potential strategy to overcome Enz resistance.
21
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis, Changxue Lu, Hao Wang et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text
Medicine, Oncology, Pharmacology +17
Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer’s disease
Pei Pang, Xiao-Ting Zhou, Fan Hu et al. · Cell Death and Differentiation · 2021 · 662 citations · Full text
Medicine, Neurobiology, Neuroscience +15